BTIG lowered the firm’s price target on Compass Pathways (CMPS) to $7 from $12 but keeps a Buy rating on the shares. The firm notes that COMP360 represents the “very careful development of a mediocre drug” relative to other options in the psychedelic and neuro-plastic pipeline, the analyst tells investors in a research note. Yesterday’s 49% decline was “a lot of movement” for a top-line announcement that was essentially as expected however, the firm added.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPS:
- Compass Pathways weakness a buying opportunity, says Canaccord
- Compass Pathways Achieves Phase 3 Trial Success
- Compass Pathways downgraded to In Line from Outperform at Evercore ISI
- Compass Pathways results ‘historic first’ for psychedelics, says H.C. Wainwright
- Compass Pathways weakness ‘significantly overdone,’ says Stifel